4/3
07:43 am
trvi
Trevi Therapeutics to Participate in Upcoming April Investor Conferences [Yahoo! Finance]
Medium
Report
Trevi Therapeutics to Participate in Upcoming April Investor Conferences [Yahoo! Finance]
4/3
07:30 am
trvi
Trevi Therapeutics to Participate in Upcoming April Investor Conferences
Medium
Report
Trevi Therapeutics to Participate in Upcoming April Investor Conferences
3/19
12:14 pm
trvi
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at B. Riley. They now have a $20.00 price target on the stock, up previously from $11.00.
Low
Report
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at B. Riley. They now have a $20.00 price target on the stock, up previously from $11.00.
3/19
08:04 am
trvi
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.50 price target on the stock.
Medium
Report
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.50 price target on the stock.
3/19
08:04 am
trvi
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its price target lowered by analysts at Needham & Company LLC from $25.00 to $24.00. They now have a "buy" rating on the stock.
Medium
Report
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its price target lowered by analysts at Needham & Company LLC from $25.00 to $24.00. They now have a "buy" rating on the stock.
3/19
08:04 am
trvi
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $21.00 price target on the stock.
Medium
Report
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $21.00 price target on the stock.
3/18
06:53 pm
trvi
Trevi Therapeutics, Inc. (TRVI) Q4 2024 Earnings Call Transcript [Seeking Alpha]
Medium
Report
Trevi Therapeutics, Inc. (TRVI) Q4 2024 Earnings Call Transcript [Seeking Alpha]
3/18
04:22 pm
trvi
Trevi Therapeutics Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Updates [Yahoo! Finance]
Low
Report
Trevi Therapeutics Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Updates [Yahoo! Finance]
3/18
04:05 pm
trvi
Trevi Therapeutics Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Updates
Medium
Report
Trevi Therapeutics Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Updates
3/16
10:28 am
trvi
Trevi Therapeutics, Inc.'s (NASDAQ:TRVI) large institutional owners must be happy as stock continues to impress, up 57% over the past week [Yahoo! Finance]
Medium
Report
Trevi Therapeutics, Inc.'s (NASDAQ:TRVI) large institutional owners must be happy as stock continues to impress, up 57% over the past week [Yahoo! Finance]
3/11
04:05 pm
trvi
Trevi Therapeutics to Report Fourth Quarter and Year End 2024 Financial Results and Provide a Corporate Update on March 18, 2025
Neutral
Report
Trevi Therapeutics to Report Fourth Quarter and Year End 2024 Financial Results and Provide a Corporate Update on March 18, 2025
3/11
10:01 am
trvi
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its price target raised by analysts at Oppenheimer Holdings Inc. from $12.00 to $20.00. They now have an "outperform" rating on the stock.
Medium
Report
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its price target raised by analysts at Oppenheimer Holdings Inc. from $12.00 to $20.00. They now have an "outperform" rating on the stock.
3/10
02:18 pm
trvi
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its price target raised by analysts at HC Wainwright from $7.50 to $12.50. They now have a "buy" rating on the stock.
Low
Report
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its price target raised by analysts at HC Wainwright from $7.50 to $12.50. They now have a "buy" rating on the stock.
3/10
09:07 am
trvi
Trevi Therapeutics meets main goal in chronic coughing treatment trial, stock surges [Seeking Alpha]
Medium
Report
Trevi Therapeutics meets main goal in chronic coughing treatment trial, stock surges [Seeking Alpha]
3/10
08:08 am
trvi
Trevi Therapeutics, Inc. (NASDAQ: TRVI) was upgraded by analysts at Raymond James from an "outperform" rating to a "strong-buy" rating. They now have a $29.00 price target on the stock, up previously from $9.00.
Medium
Report
Trevi Therapeutics, Inc. (NASDAQ: TRVI) was upgraded by analysts at Raymond James from an "outperform" rating to a "strong-buy" rating. They now have a $29.00 price target on the stock, up previously from $9.00.
3/10
08:03 am
trvi
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its price target raised by analysts at Needham & Company LLC from $8.00 to $25.00. They now have a "buy" rating on the stock.
Medium
Report
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its price target raised by analysts at Needham & Company LLC from $8.00 to $25.00. They now have a "buy" rating on the stock.
3/10
08:03 am
trvi
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its price target raised by analysts at Needham & Company LLC from $8.00 to $25.00. They now have a "buy" rating on the stock.
Medium
Report
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its price target raised by analysts at Needham & Company LLC from $8.00 to $25.00. They now have a "buy" rating on the stock.
3/10
06:00 am
trvi
Trevi Therapeutics Announces Positive Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough
High
Report
Trevi Therapeutics Announces Positive Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough
3/9
04:08 pm
trvi
Trevi Therapeutics to Host Conference Call and Webcast on March 10th to Share Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough [Yahoo! Finance]
High
Report
Trevi Therapeutics to Host Conference Call and Webcast on March 10th to Share Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough [Yahoo! Finance]
3/9
04:00 pm
trvi
Trevi Therapeutics to Host Conference Call and Webcast on March 10th to Share Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough
High
Report
Trevi Therapeutics to Host Conference Call and Webcast on March 10th to Share Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough
3/7
08:12 am
trvi
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $21.00 price target on the stock.
Low
Report
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $21.00 price target on the stock.
2/27
07:52 am
trvi
Trevi Therapeutics to Participate in Upcoming March Investor Conferences [Yahoo! Finance]
Medium
Report
Trevi Therapeutics to Participate in Upcoming March Investor Conferences [Yahoo! Finance]
2/27
07:30 am
trvi
Trevi Therapeutics to Participate in Upcoming March Investor Conferences
Medium
Report
Trevi Therapeutics to Participate in Upcoming March Investor Conferences
2/25
07:55 am
trvi
Trevi Therapeutics Completes Enrollment for Phase 2b CORAL Trial of Haduvio in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough [Yahoo! Finance]
Low
Report
Trevi Therapeutics Completes Enrollment for Phase 2b CORAL Trial of Haduvio in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough [Yahoo! Finance]
2/25
07:30 am
trvi
Trevi Therapeutics Completes Enrollment for Phase 2b CORAL Trial of Haduvio in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough
Medium
Report
Trevi Therapeutics Completes Enrollment for Phase 2b CORAL Trial of Haduvio in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough